News

Watson & Company, a digital mental care company, is pushing forward with domestic and overseas business expansion and has also started developing the insomnia electronic drug 'Focus' and medical insomnia electronic drugs.

To this end, the company recently recruited Kim Soon-joong, CEO of Danaher Mammotome Korea, as an advisory committee member and selected Professor Jeong Yong-an of Incheon Catholic St. Mary's Hospital as a clinical and technology development advisory group.

Watson & Company's 'Focus' digital mental care device is being developed for people who have difficulty taking sleeping pills due to various drug side effects, have difficulty falling asleep or maintaining sleep, and also for professional sports players.

President Kim Soon-joong is an expert with over 35 years of experience in global healthcare companies and has currently been the CEO of Danaher Mammotome Korea for 13 years. Watson & Company plans to establish a strategy for entering the global insomnia market through CEO Kim's advice.

Professor Yong-Ahn Jeong is one of the top experts in the clinical and research fields of neuromodulation in Korea, and is currently serving as the director of the Brain Intervention Center at Incheon Catholic St. Mary's Hospital. Professor Yong-Ahn Jeong is in charge of overall consulting on the direction of Focus' clinical and technical development, and is working with Watson & Company to develop and commercialize stable and effective insomnia electronic drugs.

Meanwhile, Watson & Company is a company that attracted Pre-A investment from the Technology Guarantee Fund in 2020 and was directly invested in by executives from global medical device companies and famous pharmaceutical companies in 2021. The company is currently preparing to enter the 146 trillion won insomnia global market based on various networking utilization and agile management.

Article link: http://www.e2news.com/news/articleView.html?idxno=253280